RCKT241220C30000
- 0.46
- 0.000.00%
Rocket Pharmaceuticals Newsroom
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $55
Rocket Pharmaceuticals Price Target Maintained With a $39.00/Share by Canaccord Genuity
Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Rocket Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $52
Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham
Rocket Pharmaceuticals' RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
Rocket Pharmaceuticals Analyst Ratings
Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $51
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $51
J.P. Morgan Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $49
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $29 to $52
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $45 to $55
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sight Sciences (SGHT) and Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham
Rocket Pharmaceuticals Analyst Ratings
Rocket Pharmaceuticals Initiated With an Outperform at Scotiabank